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Abstract
Background: The recent increase in whooping cough incidence (primarily caused by Bordetella pertussis) presents a
challenge to both public health practitioners and scientists trying to understand the mechanisms behind its
resurgence. Three main hypotheses have been proposed to explain the resurgence: 1) waning of protective immunity
from vaccination or natural infection over time, 2) evolution of B. pertussis to escape protective immunity, and 3) low
vaccine coverage. Recent studies have suggested a fourth mechanism: asymptomatic transmission from individuals
vaccinated with the currently used acellular B. pertussis vaccines.
Methods: Using wavelet analyses of B. pertussis incidence in the United States (US) and United Kingdom (UK) and a
phylodynamic analysis of 36 clinical B. pertussis isolates from the US, we find evidence in support of asymptomatic
transmission of B. pertussis. Next, we examine the clinical, public health, and epidemiological consequences of
asymptomatic B. pertussis transmission using a mathematical model.
Results: We find that: 1) the timing of changes in age-specific attack rates observed in the US and UK are consistent
with asymptomatic transmission; 2) the phylodynamic analysis of the US sequences indicates more genetic diversity
in the overall bacterial population than would be suggested by the observed number of infections, a pattern
expected with asymptomatic transmission; 3) asymptomatic infections can bias assessments of vaccine efficacy based
on observations of B. pertussis-free weeks; 4) asymptomatic transmission can account for the observed increase in B.
pertussis incidence; and 5) vaccinating individuals in close contact with infants too young to receive the vaccine
(“cocooning” unvaccinated children) may be ineffective.
Conclusions: Although a clear role for the previously suggested mechanisms still exists, asymptomatic transmission
is the most parsimonious explanation for many of the observations surrounding the resurgence of B. pertussis in the
US and UK. These results have important implications for B. pertussis vaccination policy and present a complicated
scenario for achieving herd immunity and B. pertussis eradication.
Keywords: Bordetella pertussis, Whooping cough, Asymptomatic infection, Phylodynamic analysis, Stochastic disease
dynamical modeling, Vaccination policy
Background
Many countries have seen a startling increase in the
incidence of Bordetella pertussis, an important causative
agent of whooping cough, over the past 20 years [1].
In the United States (US), 2012 saw more diagnosed B.
pertussis cases than in any year since 1955 (Fig. 1 and [2],
accessed 20 January 2015). The United Kingdom (UK) has
seen a similarly startling rise, with more cases occurring
in 2013 than since the vaccine refusal era of the 1970s and
*Correspondence: althouse@santafe.edu
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1980s (data available here: [3], accessed 20 January 2015).
Two general hypotheses have been proposed to explain
the rise in B. pertussis incidence: either vaccination cov-
erage is too low, where individuals remain unvaccinated
or unvaccinated susceptible individuals move into popu-
lations; or vaccinated individuals can still become infected
[1, 4]. While vaccination coverage has likely played a role
in increasing incidence, coverage has historically been
high [1, 5], raising the likelihood that the resurgence is —
at least in part — due to low vaccine effectiveness [6].
To date, three primary mechanisms have been pro-
posed to explain why vaccinated individuals can become
© 2015 Althouse and Scarpino. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Fig. 1 Increase in B. pertussis incidence over time. Panel a shows B. pertussis cases in the United States from 1922 through 2012 and in the United
Kingdom from 1940 through 2013 (from: [17] and [70]). Shaded regions correspond to the pre-vaccine era, the DTP era, and the DTaP era,
respectively. Panels b and c show the incidence of B. pertussis by age group with darker color indicating younger ages in the US and UK, respectively.
Infants less than 1 year old are labeled in darkest colors
infected with B. pertussis: 1) the vaccine mounted a
sterilizing immune response that waned over time [7],
2) the pathogen evolved to escape sterilizing immunity
induced by the vaccine [8], or 3) the vaccine failed to
induce sterilizing immunity to the pathogen [9].While the
first two mechanisms have received considerable atten-
tion, the third was only recently proposed by Warfel,
Zimmerman, and Merkel (2014) [9]. In their study, Warfel
et al. used non-human primates as a model for B. pertussis
infection, and found evidence that individuals vacci-
nated with current acellular B. pertussis vaccines (aP) can
become asymptomatically infected, and can then trans-
mit infection to susceptible individuals. The potential
for this type of vaccine failure has been observed in
humans where reanalyses of aP vaccine studies revealed
that individuals vaccinated with components of the aP
vaccine were protected against disease, but not bacterial
colonization [10, 11]. This is in addition to the extant,
but limited, evidence for natural asymptomatic infection
[12–14].
Warfel et al. point out that asymptomatic infection
in aP vaccinated individuals, and subsequent transmis-
sion, may partially account for the increase in observed
B. pertussis incidence. However, from a public health
perspective, the presence of vaccine-induced or natu-
rally infected asymptomatic individuals who transmit
disease could have consequences beyond facilitating an
increase in incidence. In response to Warfel et al.,
Domenech de Cellès et al. (2014) [15] argue that a
reduction in incidence among unvaccinated individuals
in a population with high aP coverage shows that aP
must reduce B. pertussis transmission to some extent.
It may be that aP vaccinated infected people are less
efficient at transmitting B. pertussis compared with unvac-
cinated infected people, though it is not clear to what
extent [16].
Here, we examine incidence and genetic data to
provide empirical support for asymptomatic transmis-
sion and then construct mathematical models of B.
pertussis transmission to explore the public health con-
sequences of asymptomatic transmission. Our results
suggest that: 1) there is strong empirical support for
asymptomatic transmission from both the epidemio-
logical and genomic data; 2) the presence of asymp-
tomatic transmitters will bias estimates of vaccine efficacy
derived from observations of stochastic fadeouts across
cities; and 3) asymptomatic transmission provides the
most parsimonious explanation for many of the observed
patterns associated with current B. pertussis dynamics
in the US and UK (that is, the resurgence of cases,
the changes in age-specific attack rates, the observed
level of bacterial genetic variation, and the failure of
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ring-vaccinating, or “cocooning”, unvaccinated infants).
The results on vaccination have important public health
and clinical implications, especially related to recommen-




All reported B. pertussis cases in the United States from
1922 through 2012 were obtained from the US Cen-
ters for Disease Control (CDC) [17], and all reported B.
pertussis cases for the United Kingdom from 1940 through
2013 were obtained from Public Health England (PHE,
data available here: [18], accessed 8 October 2014). Age-
specific B. pertussis incidence was obtained from the
CDC and the PHE. Population sizes for the denom-
inators were obtained from the US Census through
the CDC, and for the UK from the UK Office for
National Statistics (data available here: [19], accessed 8
October 2014). Historic US incidence data come from the
CDC’s Public Health Reports and Morbidity and Mortal-
ity Weekly Reports (MMWR), digitized and downloaded
from Project Tycho [20, 21].
Themodel
We formulate deterministic and stochastic Susceptible,
Infected, Removed (SIR) models of B. pertussis transmis-
sion [22–24]. Briefly, susceptible individuals are born at
rate μ, where they are vaccinated with either the whole-
cell (wP) or acellular (aP) B. pertussis vaccine, depend-
ing on which vaccine is currently in use. Our model
includes three vaccine epochs: one without vaccination,
one with only wP vaccination, and one with only aP vac-
cination. These epochs are non-overlapping, similar to
the advent of wP and its replacement by aP [25]. We
assume those vaccinated with wP are completely immune
to infection (see Discussion). Those vaccinated with aP
move into a vaccinated class where they can become
asymptomatically infected (that is, they incur a direct
benefit from vaccination because they will not develop
symptomatic disease [26, 27]). Unvaccinated individuals
become infected with B. pertussis at rate β and become
symptomatic with probability σ (sensitivity to which is
explored in the supplementary information Additional
file 1), and aP vaccinated individuals become asymp-
tomatically infected at rate β . We assume no difference in
transmissibility between symptomatic and asymptomatic
individuals (see Discussion and Additional file 1). Individ-
uals recover from symptomatic and asymptomatic infec-
tion at rates γs and γa. Individuals die at rate ν, which
we set equal to μ to keep the population size con-
stant. Individuals can wane from protective immunity at
rate ω. The equations governing transmission dynamics
are:
S′(t) = μ · (1 − wP − aP) − β[ Is(t) + Ia(t)] S(t)
+ωR(t) − νS(t) (1)
I ′s(t) = βσ [ Is(t) + Ia(t)] S(t) − γsIs(t) − νIs(t) (2)
I ′a(t) = β(1 − σ)[ Is(t) + Ia(t)] S(t) + β[ Is(t) + Ia(t)]
V (t) − γaIa(t) − νIa(t) (3)
V ′(t) = μ · aP − β[ Is(t) + Ia(t)]V (t) − νV (t) (4)
R′(t) = μ · wP + γsIs(t) + γaIa(t) − ωR(t) − νR(t) (5)
We assume that the aP vaccine has 100% efficacy in pre-
venting disease; however, this is a conservative assump-
tion with respect to our conclusions. We formulate both
deterministic and stochastic (Gillespie stochastic simula-
tion algorithm [28] with the binomial tau-leap approxima-
tion [29]) versions of the model. Analytical expressions for
the basic reproduction number (R0) and model equilibria
are given in Additional file 1.
Phylodynamic analysis
We fit a series of phylodynamic models to concate-
nated single nucleotide polymorphisms (SNPs) identified
from whole B. pertussis genome sequences isolated from
patients infected in the US between 1935 and 2005 [30].
The resulting data set contained 36 isolates: 2 from the
pre-vaccine era, 8 from the wP vaccine era, and 26 from
the aP vaccine era, each with a nucleotide length of 5,414
bases. Sequencing, alignment, and variant calling were all
performed by Bart et al. (2014) [30].
Using this data set, we inferred the parameters of
a phylodynamic model using Bayesian Markov chain
Monte Carlo (MCMC) methods implemented in BEAST
2.1 [31] with a Hasegawa-Kishino-Yano (HKY) substitu-
tion model, as suggested by jModelTest 2.1 [32], and a
birth-death skyline tree model with serial sampling [33].
The underlying model is a stochastic birth-death pro-
cess, which is the same underlying stochastic process for
models such as SI, SIR, and SEIR. We are interested in
two parameters: the birth rate, which is the rate at which
new cases enter the population through transmission; and
the sampling rate, which is the rate at which cases leave
the population because they are sampled. We make the
assumption that sampling a case, that is, collecting B.
pertussis bacteria and sequencing the genome, removes
that infected individual from the population. This is an
assumption, but it appears logical: once an individual is
diagnosed with whooping cough, and B. pertussis isolated,
the individual is no longer transmitting due to having
cleared the infection, or being socially removed from
susceptible individuals. Convergence of the model was
obtained with two independentMCMC runs of more than
75 million generations and confirmed with effective sam-
ple size (ESS) values above 200 calculated with TRACER
v1.6. Similar results were obtained using both a relaxed
lognormal and relaxed exponential molecular clock [34].
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Results
Empirical evidence of asymptomatic transmission
Despite its perceived importance, ascertaining evidence
for asymptomatic transmission for any disease remains a
challenge. This has been especially true with B. pertussis,
where identifying individuals asymptomatically infected
has historically been difficult [12–14]. Perhaps the most
compelling piece of evidence for asymptomatic trans-
mission is the documented failure of cocooning to
protect newborns [35, 36], which can only be parsi-
moniously explained by asymptomatic transmission [9].
Other empirical patterns are expected — in both inci-
dence and genetic data — if asymptomatic transmission is
occurring as a result of the aP vaccine preventing symp-
tomatic disease, but failing to block transmission. Here we
provide empirical observations, which are both consistent
with and in total most parsimoniously accounted for by
asymptomatic transmission.
Figure 2 shows a wavelet analysis of B. pertussis inci-
dence in the UK in unvaccinated and under-vaccinated
infants (< 1 year old), both considered indicators of over-
all B. pertussis transmission in a population [37]. As wP
vaccine coverage increases to greater than 90% (from the
early 1980s to the early 1990s) we see a disruption of
the natural approximately 4-year periodicity of B. pertus-
sis cases driven by susceptible turnover [38, 39]. How-
ever, the switch from wP to aP in the UK coincides with
the return of cyclic patterns, which are similar to the
approximately 4-year periodicity seen in the pre-vaccine
era.
A second line of evidence comes from changes in
age-specific attack rates in the US and UK. Both coun-
tries switched to the aP vaccine; however, the US switch
occurred seven years before the UK switch. Changes in
age-specific attack rates are observed in both countries
after switching to the aP vaccine, and appear similar when
viewed as time since the switch to aP (Fig. 3). Another
important facet of these data is that within both countries
the rise in attack rates is synchronous across age groups.
These two observations would be an expected conse-
quence of asymptomatic transmission from aP vaccinated
individuals as fully aP vaccinated individuals become old
enough to attend school and become infected. These
observations are challenging to explain with either wan-
ing immunity or pathogen evolution alone; for example,
waning immunity should most often induce asynchrony
in age-specific attack rates [22]. Increases in incidence
could be explained by heterogeneous vaccine coverage or
Fig. 2 Disruption of B. pertussis cycles by vaccination. Panel a shows the square root of B. pertussis cases in infants less than 1 year old in the United
Kingdom from 1982 through 2013 (in black) and the percentage vaccine coverage over the same period (in blue). Vertical dashed line indicates the
switch to an aP vaccination schedule. Panel b shows the standard wavelet spectrum of the incidence in panel a; panel c shows the Fourier
spectrum of the incidence. As vaccination coverage increases (1985 through about 1991) we see a decrease in the power of cycles of approximately
4 years. We begin to see an increase in this power after the introduction of aP vaccination in 2004, suggesting transmission patterns similar to those
observed in the pre-transmission-blocking vaccine era

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Fig. 3 Increase in B. pertussis incidence after switch to aP vaccination. Figure compares the incidence of B. pertussis after the switch to aP vaccination
in the US (panel a) and the UK (panel b). Time since the switch is presented on the x-axis. Note the similarities in the timing of spikes in incidence
after the switch to aP vaccination
changing vaccine effectiveness, which we are assuming in
switching from the wP to aP vaccine.
Lastly, we find evidence consistent with asymptomatic
transmission using the results of a transmission-oriented
phylodynamic model [31] fit to 36 US B. pertussis
genomes [30]. Asymptomatic transmission is expected
to cause a mismatch between incidence estimated from
case data and incidence reconstructed from genetic
data. Intuitively, this happens because the population
genetic variation of the bacteria is a function of the
entire infected population size, while case data can
only come from symptomatic individuals. This is true
even if bacterial sequences are only collected from
symptomatic individuals, assuming asymptomatic and
symptomatic individuals are mixing with each other.
The observed pattern can only be accounted for by
asymptomatic transmission or underreporting. Because
whooping cough reporting has increased in recent years
[40, 41], asymptomatic transmission remains the only
plausible explanation for the observed population
genomic pattern.
Figure 4 shows the changes in sampling and rates since
the mid-1960s for the US. We see an increase in the birth
rate after the switch to aP, as expected given the rise in
incidence; however, we see a decrease in the sampling rate
after the switch to aP. This mismatch between the birth
rate and sampling rate indicates that, despite increasing
numbers of new B. pertussis cases, the fraction of cases
identified decreases. Importantly, the estimated decrease
in the sampling rate coincides with the time-window con-
taining the largest number of sampled bacteria and in an
era with the greatest accuracy in the laboratory methods
used in diagnosing B. pertussis cases [42]. This finding
is indicative of an increase in the overall genetic diver-
sity of B. pertussis in the population after the US switched
from the wP to the aP vaccine. Natural selection favor-
ing a vaccine escape variant would be expected to reduce
the genetic variation and increase the estimated sampling
rate, as seen in Australia by Bart et al. [30]. Addition-
ally, waning immunity could result in an increase in the
genetic diversity of the bacterial population; however,
without systematic underreporting it would not result

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Fig. 4 Phylodynamic analyses. Figure shows the sampling rate and birth rate derived from the BEAST analysis for the 36 US B. pertussis genomes. Solid
white lines with square boxes indicate the posterior median, with the shaded region indicating the 95% highest posterior density. Darker colors are
associated with regions of higher posterior density, with the shape representing the actual posterior density. Despite the birth rate remaining higher
after the switch to aP, the sampling rate declines. This pattern would be expected with an increasing rate of asymptomatic transmission
in a lower estimated sampling rate. Again, we conclude
that asymptomatic transmission remains the only par-
simonious explanation for the observed phylodynamic
patterns.
Consequences of asymptomatic transmission: biased
estimates of vaccine effectiveness
Historically, a key indicator of success for vaccination pro-
grams is a reduction in pathogen transmission in popula-
tions, as measured by the mean proportion of disease-free
weeks [24, 43, 44]. Figure 5 presents the proportion of
reported B. pertussis-free weeks (fade-outs, panel a) and
mean duration of fade-outs (panel b) for the 50 US states
in pre-vaccine (1920–1945) and post-vaccine (2006–2013)
epochs. The pre-vaccine epoch clearly has fewer weeks
with no reported B. pertussis cases than does the mod-
ern vaccine epoch. This has been widely interpreted as
evidence for decreasing levels of B. pertussis transmis-
sion and some degree of herd immunity afforded by the
vaccine [7, 15, 44]. However, if situational awareness is
impaired by a vaccine that protects against symptomatic
disease but does not block transmission, interpreting
reported B. pertussis-free weeks can be misleading.
Figure 6 presents the results of stochastic simulations
of the model across various population sizes. Compar-
ing the observed symptomatic cases in the no vaccine
and aP vaccine eras, we see results qualitatively similar to
empirical data [44]: introduction of aP vaccine leads to a
higher proportion of B. pertussis-free weeks across pop-
ulation sizes (Kolmogorov-Smirnov [KS] test, D = 0.46,
p = 1.2 · 10−9; panel a). However, examination of the
asymptomatic population (the true burden) reveals many
fewer weeks with no cases of B. pertussis (KS test, D =
0.53, p = 1.2 · 10−12; panel b), which is in fact not differ-
ent from the pre-vaccine era (KS test, D = 0.07, p = 0.97;
panel c).
Figure 7 demonstrates the percentage of the true infec-
tions observed at steady state ([Observed Incidence/Total

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Fig. 5 Comparing disease-free weeks in pre- and post-vaccination
scenarios. Panel a shows the proportion of disease-free weeks
(fade-outs) per year for the 50 US states in the pre-vaccine (1920–1945,
black points and line) and post-vaccine (2006–2013, blue points and
line) eras. Lines indicate best-fit exponential curves. Panel b shows
the mean duration of consecutive disease-free weeks in both eras
Incidence-1]*100) as aP vaccination rate increases and the
probability of symptomatic infection (σ ) increases. We
find that for realistic aP coverage rates (between 85%
and 95%), the percentage of total cases expected to be
observed is low (< 15%), and is highly dependent on
the probability of an infection becoming symptomatic (a
parameter that is generally not known). These results are
likely to be conservative given the low, but unknown,
diagnosis rate of asymptomatic infections and known
underreporting of symptomatic infections in adults [45].
Consequences of asymptomatic transmission: increased B.
pertussis incidence
Figure 8 illustrates the fold increase in observed symp-
tomatic and unobserved asymptomatic infections after
transitioning from a wP to an aP vaccine at equilibrium.
This is calculated by dividing the number of symptomatic
or asymptomatic cases with various levels of aP coverage
Fig. 6 Changes in transmission in pre- and post-vaccination
scenarios? Figure shows the proportion of disease-free weeks
(fade-outs) for various population sizes from the stochastic
formulation of the model. Panel a compares the symptomatic cases
in the aP vaccination era with those in the pre-vaccine era; panel b
compares the symptomatic to asymptomatic cases in the vaccine era;
panel c compares the asymptomatic cases in the post-vaccine era
with those in the pre-vaccine era. These results demonstrate no
changes in transmission due to vaccination. Parameters: birth rate (μ)
= death rate (ν) = 1/75 years−1; recovery rates for symptomatic (γs)
and asymptomatic (γa) = 14 days−1; probability of symptomatic
infection (σ ) = 0.25; transmissibility (β) is calculated per value of R0

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Fig. 7 How does an inefficient vaccine affect situational awareness?
Figure shows the percent difference in observed infections
(symptomatic) from true infections (symptomatic + asymptomatic) at
steady state as aP vaccination rate increases and the probability of
symptomatic infection increases. Shaded area indicates a range of
reasonable aP vaccination rates. At current aP vaccination coverage
levels, the majority of cases are asymptomatic and therefore
undetected. See Additional file 1 for model details. Parameters: birth
rate (μ) = death rate (ν) = 1/75 years−1; recovery rates for
symptomatic (γs) and asymptomatic (γa) = 14 days−1; baseline wP
vaccination rate = 0.9; transmissibility (β) is calculated such that
R0 = 18. Note that previously published values of R0 for pertussis
range from 16–20 [71] to closer to 5 in some populations [72]
(reported on the x-axis) and 0% wP coverage by the num-
ber of cases with 90% wP coverage and 0% aP coverage.
This is done to simulate the switch from wP to aP in the
US andUK (going from high wP coverage to coverage with
aP), and indicates that a change in vaccine could partially
account for the rise in cases.
As aP vaccination coverage increases, asymptomatic
infections increase up to nearly 30-fold. We see a sub-
stantial increase in the observed numbers of symptomatic
cases after wP vaccination is replaced by aP vaccina-
tion. At low to moderate levels of aP vaccination, there
is a 5- to 15-fold increase in symptomatic cases. Only
at extremely high levels of aP vaccination (> 99%) is
there no change in symptomatic infections. This is in line
with the observed rise in B. pertussis incidence: cases in
2012 were 5.4-fold (95% bootstrap confidence interval:
0.4–13.3) higher than cases in years 1985 through 1995
([46]). This result is similar to previous findings by van
Boven et al. (2005) [47], who found that as wP vaccination
coverage increased, primary infections (symptomatic)
decreased, while secondary infections (subclinical, or
asymptomatic) increased.
Fig. 8 Can an inefficient vaccine lead to increased transmission?
Figure demonstrates the fold increase in observed symptomatic and
unobserved asymptomatic infections after transitioning from a wP to
an aP vaccine. This is calculated by dividing the number of
symptomatic or asymptomatic cases with various levels of aP
coverage (reported on the x-axis) and 0% wP coverage by the
number of cases with 90% wP coverage and 0% aP coverage. This
was designed to simulate the switch from wP to aP in the US and UK
(going from high wP coverage to coverage with aP). We see an
increase in symptomatic cases across a large range of aP vaccination
coverage levels. See Additional file 1 for model details. The gray band
indicates the empirical 5.4-fold (95% bootstrap confidence interval:
0.4–13.3) increase in cases in the US comparing 2012 to the years
1985 through 1995. The model recreates the observed increase in
cases. Parameters: birth rate (μ) = death rate (ν) = 1/75 years−1;
recovery rates for symptomatic (γs) and asymptomatic (γa) = 14
days−1; probability of symptomatic infection (σ ) = 0.25; baseline wP
vaccination rate = 0.9; transmissibility (β) is calculated such that
R0 = 18
Effects of waning immunity to B. pertussis
It is clear that waning immunity plays a role in the
epidemiology of B. pertussis, though estimates of the
duration of protection to B. pertussis are highly varied
[7, 15, 48]. Because the exclusion of waning immunity
was a conservative modeling assumption, we focused
our analysis on a model where immunity due to vac-
cination was lifelong. However, as Fig. 9 demonstrates,
the inclusion of waning immunity increases symptomatic
infections up to 12% and asymptomatic infections up to
8%. Importantly, waning immunity would not explain the
failure of infant cocooning strategies, the synchrony in
age-specific attack rates after the switch to the aP vaccine
as presented above, or the observed B. pertussis genomic
patterns.

Althouse and Scarpino BMCMedicine Page 9 of 12
Fig. 9 Effects of including waning immunity on symptomatic and asymptomatic infections. Figure shows percent increases in symptomatic and
asymptomatic cases at equilibrium after the switch to aP vaccination with inclusion of waning immunity. Parameters: birth rate (μ) = death rate (ν)
= 1/75 years−1; recovery rates for symptomatic (γs) and asymptomatic (γa) = 14 days−1; probability of symptomatic infection (σ ) = 0.25; baseline
wP vaccination rate = 0.9; transmissibility (β) is calculated such that R0 = 18
Discussion
In this paper, we have presented empirical evidence —
from both case and genomic data — for asymptomatic
B. pertussis transmission following the switch from the
wP to the aP vaccine in the US and UK. Then, using
mathematical and computational transmission models,
we have demonstrated that an aP vaccine which blocks
symptomatic disease but not asymptomatic transmission
is able to account for the observed increase in B. pertussis
incidence; complicates situational awareness surrounding
levels of current B. pertussis transmission; and poten-
tially biases estimates of vaccine efficacy obtained from
case data. When coupled with the laboratory results on
asymptomatic transmission in non-human primates from
Warfel et al. (2014) and evidence from cross-sectional,
human studies in China by Zhang et al. (2014) [12], we
conclude that asymptomatic transmission from aP vacci-
nated individuals to fully susceptible individuals provides
the most parsimonious explanation for the observed
resurgence of B. pertussis in the US and UK, the changes
in age-specific attack rates, the observed increase in B.
pertussis genetic variation, and the multiply demon-
strated failure of cocooning unvaccinated infants
[35, 36].
Our observation of increased cases due to asymp-
tomatic or subclinical infections has been noted in
previous studies of wP vaccination [47–49], as well as
examinations of the effects of natural and vaccine-induced
protection on the duration of immunity [4, 50]. While
these previous studies suggest that asymptomatic infec-
tions may account for an increase in whooping cough
incidence, they do not provide strong evidence of asymp-
tomatic transmission and do not discuss the failure of
infant cocooning. Also, these studies were focused on
cases occurring during the wP vaccine era.
There are several limitations to the data presented in
this study. First and foremost is a lack of publicly available
data to more fully explore the hypotheses suggested. This
lack of available data is well known among researchers
studying B. pertussis [51]. Longer time series of age-
stratified data (specifically in infants too young to be
vaccinated) would be required to fully explore how the
natural periodicity of B. pertussis incidence shifted as
wP coverage changed. However, these data either do not
exist or are unavailable to researchers. A second issue is
that clearly not enough time has elapsed since the switch
to aP to draw definitive conclusions about the resump-
tion of cycles of B. pertussis incidence. While the data
appear most consistent with asymptomatic transmission
from aP vaccinated individuals, it may be many years
before enough time has elapsed to be able to rule out this
hypothesis.
In this study we focused on the United States and
the United Kingdom where B. pertussis incidence has
increased in the past 20 years. We acknowledge that
this resurgence is not universal and that countries vary
greatly in reporting rates, vaccine composition or sched-
ule, historical and current vaccination coverage levels, and
the genetic diversity of B. pertussis strains [1]. The ini-
tial increase in US B. pertussis cases also began before
the aP switch. However, the empirical evidence we pre-
sented, specifically the phylodynamic results, wavelet
analysis, changing attack rates, and failure of cocoon-
ing, all occurred after the aP switch. It may also be the
case that a large factor in the observed resurgence is the
improvement in B. pertussis diagnostics; however, this

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would not explain the bulk of the empirical evidence pre-
sented here. Disentangling the effects of this variation, in
order to evaluate hypotheses to explain the resurgence,
will require high resolution case and genetic data. The
US and UK have the largest, publicly available, sufficiently
granular data, but only the US had a sufficient number of
B. pertussis genomes available to conduct phylodynamic
analyses.
Although the phylodynamic results from the US provide
support for an increase in the asymptomatic population
size after the switch to the aP vaccine, that analysis has
a number of important caveats. First, genomic data were
only available through 2005, leaving nearly the last decade
without samples. Second, although the posterior median
estimate of the sampling rate decreases drastically after
the switch to the aP vaccine, the 95% highest posterior
densities overlap. As a result, we are unable to statisti-
cally conclude that sampling rates are lower. Third, an
increase in underreporting could also explain a decrease
in the estimated sampling rate; however, due to changes in
B. pertussis diagnostics [1, 42] it is unlikely that there has
been a substantial decrease in underreporting coinciding
with the aP switch. Nevertheless, the well-documented
issues associated with underreporting of B. pertussis cases
in adults remains an important area for future phylo-
dynamic studies [52]. Lastly, data availability prevented
us from performing phylodynamic analyses in different
countries. For example, predictions could be tested for
those countries where: a resurgence is also occurring
(such as the UK) [1], case counts remain fairly constant
and low (such as Italy) [1], molecular evidence high-
lights the importance of vaccine escape (such as Australia)
[30, 53], and where the wP vaccine is still in use (such as
Kenya) [54].
As is the case with all models, the one used in this
study makes a number of simplifying assumptions. How-
ever, most of these assumptions render our conclusions
conservative. We assume that wP vaccination is 100%
effective, which is not the case [55]. Relaxing this assump-
tion is analogous to having lower coverage overall, and
thus our estimates of fold increase after the aP switch
are conservative. Our model does not explicitly account
for evolution of the B. pertussis bacterium [7, 56] — a
factor which may play a large role in the epidemiolog-
ical dynamics of B. pertussis. For example, it has been
posited that B. pertussis has adapted to vaccination in
several European countries. Mooi et al. (2001) identi-
fied genetic changes between pre- and post-vaccination
strains of B. pertussis [8]. Despite this evidence, includ-
ing evolution would merely increase the number of
individuals susceptible to both symptomatic and asymp-
tomatic infection and would yield exactly the oppo-
site pattern of population genomic variation than seen
empirically.
Our model also assumes that symptomatic and asymp-
tomatic infections have the same basic reproduction
number. Asymptomatic or subclinical/misdiagnosed indi-
viduals may spread B. pertussis through direct contact,
breathing, or coughing [57]. Although coughing may
increase transmission, the total bacterial load in the
nasopharynx ofB. pertussis-infected non-human primates
is similar between symptomatic and asymptomatic indi-
viduals (see Figure one, panel a in [9]). The same study
suggested that the duration of higher bacterial loads may
be longer in asymptomatic individuals, and that there
may not be differences in routes of transmission between
asymptomatic and symptomatic individuals. However,
and perhaps more importantly, being asymptomatic sug-
gests that individuals may not alter their behavior and thus
contact more individuals than a symptomatic individ-
ual [58]. Therefore, it seems equally plausible to conclude
that the R0 for aP vaccinated individuals is higher [47].
Future studies should make estimating the distribution
of effective reproductive numbers for symptomatic and
asymptomatic individuals a priority.
It is important to note that distinguishing true
asymptomatic infections from attenuated, symptomatic
infections, especially in older age groups, is challenging. If
infections were truly asymptomatic, interventions based
on teaching clinicians about the potential range of clini-
cal presentations of B. pertussis infection would not work,
while proper identification of attenuated symptomatic
infections could allow for proper increased use of pro-
phylactic measures. Finally, our study assumes a constant
probability of symptomatic infection, whereas previous
work has shown the probability of becoming symptomatic
may depend on the history of exposures of an individ-
ual [59]. Future work should explore the probability of
symptomatic infection and its potential changes over the
life of an individual.
Conclusions
That there has been a rise in whooping cough incidence
in many countries around the globe is irrefutable. The
findings presented in Warfel et al., in conjunction with
ours, have profound implications for the understanding
of B. pertussis transmission dynamics and for vaccina-
tion policy. Specifically, our results would explain the
negative outcomes found in recent studies of postnatal
cocooning [35, 36] and would further complicate efforts
to achieve herd immunity and possible eradication [60].
Long-term solutions to B. pertussis vaccination are neces-
sary, and new vaccines are in development [61, 62]. In the
years before a new vaccine is ready for clinical use, other
options are necessary for reducing incidence, includ-
ing vaccination of pregnant women [63, 64] or poten-
tially a switch back to wP vaccination as a priming dose
[65–67].
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Clearly, more research is necessary, but if our results
hold, public health authorities may be facing a situation
similar to that of polio, where vaccinated individuals can
still transmit infection [68]. This suggests further modi-
fications of recommendations to clinicians for protecting
unvaccinated children [69] and ensuring that aP cover-
age remains high. Our results on the potential surveillance
bias associated with B. pertussis incidence highlight a crit-
ical need for population-wide serological surveys to detect
recent infection, studies to examine the genetic diversity
of the B. pertussis bacterium, more detailed studies of the
incidence rate in unvaccinated individuals, and increased
active surveillance of attenuated symptomatic B. pertus-
sis infections. In light of current evidence and our results,
we cannot dismiss the potential far-reaching epidemio-
logical consequences of asymptomatic transmission of B.
pertussis and an ineffective B. pertussis vaccine.
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